Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Stock market today: Dow, S&P 500, Nasdaq rise as Fed meeting kicks off, JOLTS data shows openings rose

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq rise as Fed meeting kicks off, JOLTS data shows openings rose US stocks turned into the green Tuesday morning as the Federal Reserve's December policy meeting kicked off and federal data showed job openings unexpectedly ticked higher even as layoffs jumped…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Snacks business continues to weather category softness but brands remain highly relevant

    80% confidence

  • It would be irresponsible to set out plans for the next six months regarding monetary policy

    80% confidence

  • Housing market is experiencing soft demand and choppy conditions this year

    80% confidence

  • Luxury homebuilding business remains differentiated despite market conditions

    80% confidence

  • Consumers remain intentional in their shopping behaviors with at-home-cooking trends continuing to benefit brands

    80% confidence

  • Moscow is planning to continue sending uninterrupted fuel supplies to India

    80% confidence

  • Would be looking for a new Fed chair to immediately move to cut rates

    80% confidence

  • Americans' affordability concerns are a con job

    80% confidence

Data points we hold from this source

Dow Jones Industrial Average · stock movement0.35 percent
Donald Trump · approval rating economy39.8 percent
Donald Trump · disapproval rating economy57.6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq rise as Fed meeting kicks off, JOLTS data shows openings rose — Source | Via News | Finance Via News